Health
Baricitinib drug can reduce mortality in patients with moderate to severe COVID-19 – News-Medical.Net
The rheumatoid arthritis drug baricitinib can block viral entry and reduce mortality in patients with moderate to severe COVID-19, according to translational research…
Reviewed by Emily Henderson, B.Sc.Nov 16 2020
The rheumatoid arthritis drug baricitinib can block viral entry and reduce mortality in patients with moderate to severe COVID-19, according to translational research by an international team coordinated by researchers from Karolinska Institutet in Sweden.
The findings, published in the journal Science Advances, support the continuation of ongoing randomized clinical trials.
“We are pleased to report a 71 percent reduction in mortality for the group…
-
Business23 hours agoWhere will Berkshire Hathaway be in 1 year?
-
Noosa News18 hours agoTwo trapped and fighting for life after major three-vehicle crash in Brisbane
-
Business19 hours agoUp 105% in a year, are Pro Medicus shares still a good buy today?
-
Noosa News14 hours agoQueensland man sentenced to four years imprisonment after string of terror offences